Abiomed (FRA:AIO) Common Stock : €0 Mil (As of Sep. 2022)

View and export this data going back to 1987. Start your Free Trial

What is Abiomed Common Stock?

Abiomed's quarterly common stock increased from Mar. 2022 (€0 Mil) to Jun. 2022 (€0 Mil) and increased from Jun. 2022 (€0 Mil) to Sep. 2022 (€0 Mil).

Abiomed's annual common stock declined from Mar. 2020 (€0 Mil) to Mar. 2021 (€0 Mil) but then increased from Mar. 2021 (€0 Mil) to Mar. 2022 (€0 Mil).

Abiomed Common Stock Historical Data

The historical data trend for Abiomed's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abiomed Common Stock Chart

Abiomed Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Common Stock

Get a 7-Day Free Trial

0.36

0.40

0.41

0.38

0.41

Abiomed Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Common Stock	Get a 7-Day Free Trial															0.39	0.40	0.41	0.43	0.46

Abiomed Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Abiomed (FRA:AIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abiomed Inc (FRA:AIO) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

22 Cherry Hill Drive, Danvers, MA, USA, 01923

Website

https://www.abiomed.com

Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.